CD33 and leukemia: Previous studies reported that CAR-T cells targeted CD33/CD123, which antigens targeted both leukemia cells and hematological stem cells, indicating CD33/CD123 CAR-T treatment might result in the bone marrow failure (Pizzitola et al., 2014).